MRK•benzinga•
Merck Announces Its Mk-1084 Shows Manageable Safety Profile And Antitumor Activity In Phase 1 Trial Of Patients With Advanced Colorectal Cancer And Non-Small Cell Lung Cancer Whose Tumors Harbor KRAS G12C Mutation
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on May 30, 2025 by benzinga